Clostridium difficile (klos-TRID-e-um dif-uh-SEEL), often called C. difficile or C. diff, is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon.
Risk factors for infection include antibiotic or proton pump inhibitors use, hospitalization, other health problems, and older age.
A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment of Clostridium difficile infection (CDI).
SPONSOR: Summit Limited, UK.
STATUS: Open , enrolling now..!
TRIAL PERIOD: 3 MONTHS.